(-)-Boldine

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 阿朴菲
• 英文名称: (-)-Boldine
• 英文别名: (6aR)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
• 化学式: C₁₉H₂₁NO₄
• 分子量: 327.38
• InChiKey: LZJRNLRASBVRRX-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (-)-Boldine 、 碘甲烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 24.0h， 以70%的产率得到2.3.5.6-Tetramethoxy-8-<β-trimethylammonium-aethyl>-phenanthren
  参考文献：
  名称：

  PHENANTHRENE DERIVATIVES FOR USE AS MEDICAMENTS

  摘要：

  本发明涉及苯并并芘衍生物作为药物的用途，主要用于预防和/或治疗肌无力型1型、亨廷顿病类2型、脊髓小脑共济失调型8型、肌无力型2型、脊髓小脑共济失调型3型、脆性X相关震颤/共济失调综合征、额颞叶退行性/肌萎缩侧索硬化和脊髓小脑共济失调型31型。在一个首选实施例中，本发明的苯并并芘衍生物也用作抗肌无力剂。因此，本发明可包括在整个制药或医学领域中。

  公开号：

  US20160194274A1

文献信息

• Phenanthrene derivatives for use as medicaments
  申请人：Valentia Biopharma

  公开号：EP2742974A1

  公开（公告）日：2014-06-18

  Phenanthrene derivatives of formula I for use as medicaments. The present invention refers to phenanthrene derivatives for use as medicaments, mainly in the prevention and/or treatment of DM1, HDL2, SCA8, DM2, SCA3, FXTAS, FTD/ALS, and SCA31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents.

  公式I的菲南三烯衍生物用作药物。本发明涉及用作药物的菲南三烯衍生物，主要用于预防和/或治疗DM1、HDL2、SCA8、DM2、SCA3、FXTAS、FTD/ALS和SCA31。在一个优选实施例中，本发明的菲南三烯衍生物也用作抗肌肉张力剂。
• TCM Active Ingredient Oxoglaucine Metal Complexes: Crystal Structure, Cytotoxicity, and Interaction with DNA
  作者：Zhen-Feng Chen、Yan-Fang Shi、Yan-Cheng Liu、Xue Hong、Bo Geng、Yan Peng、Hong Liang

  DOI：10.1021/ic200443p

  日期：2012.2.20

  The alkaloid oxoglaucine (OG), which is a bioactive component from traditional Chinese medicine (TCM), was synthesized by a two-step reaction and used as the ligand to react with transition metal salts to give four complexes: [OGH][AuCl4]center dot DMSO (1), [Zn(OG)(2)(H2O)(2)](NO3)(2) (2), [Co(OG)(2)(H2O)(2)](ClO4)(2) (3), and [Mn(OG)(2)(H2O)(2)](ClO4)(2) (4). The crystal structures of the metal complexes were confirmed by single crystal X-ray diffraction. Complex 1 is an ionic compound consisting of a charged ligand [OGH](+) and a gold complex [AuCl4](-). Complexes 2-4 all have similar structures (inner-spheres), that is, octahedral geometry with two OG coordinating to one metal center and two aqua ligands occupying the two apical positions of the octahedron, and two NO3- or ClO4- as counteranions in the outer-sphere. The complexation of OG to metal ion was confirmed by ESI-MS, capillary electrophoresis and fluorescence polarization. The in vitro cytotoxicity of these complexes toward a various tumor cell lines was assayed by the MTT method. The results showed that most of these metal-oxoglaucine complexes exhibited enhanced cytotoxicity compared with oxoglaucine and the corresponding metal salts, with IC50 values ranging from 1.4 to 32.7 mu M for sensitive cancer cells, which clearly implied a positive synergistic effect. Moreover, these complexes appeared to be selectively active against certain cell lines. The interactions of oxoglaucine and its metal complexes with DNA and topoisomerase I were investigated by UV-vis, fluorescence, CD spectroscopy, viscosity, and agarose gel electrophoresis, and the results indicated that these OG-metal complexes interact with DNA mainly via intercalation. Complexes 2-4 are metallointercalators, but complex 1 is not. These metal complexes could effectively inhibit topoisomerase I even at low concentration. Cell cycle analysis revealed that 1-3 caused S-phase cell arrest.
• [EN] THERAPEUTIC METHODS AND COMPOSITIONS<br/>[FR] MÉTHODES ET COMPOSITIONS THÉRAPEUTIQUES
  申请人：UNIV CONCEPCION

  公开号：WO2010026487A1

  公开（公告）日：2010-03-11

  Disclosed herein are methods for treating a sexual dysfunction or Parkinson's disease; methods for enhancing erectile function; methods of stimulating erectile response and methods for inducing emesis that involves the administration of boldine, a derivative or a pharmaceutically acceptable salt thereof in an amount effective to treat sexual dysfunction or Parkinson's disease; enhance erectile function; stimulate erectile response or induce emesis.
• [EN] PHENANTHRENE DERIVATIVES FOR USE AS MEDICAMENTS<br/>[FR] UTILISATION DE DÉRIVÉS DE PHÉNANTHRÈNE COMME MÉDICAMENTS
  申请人：VALENTIA BIOPHARMA

  公开号：WO2014091020A1

  公开（公告）日：2014-06-19

  The present invention refers to phenanthrene derivatives for use as medicaments, in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spinocerebellar Ataxia Type 3, Fragile-X- Associated Tremor/ Ataxia Syndrome, Frontotemporal Degeneration/Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia Type 31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents. Therefore, this invention may be included either in the whole pharmaceutical or medical field.
• PHENANTHRENE DERIVATIVES FOR USE AS MEDICAMENTS
  申请人：VALENTIA BIOPHARMA

  公开号：US20160194274A1

  公开（公告）日：2016-07-07

  The present invention refers to phenanthrene derivatives for use as medicaments, mainly in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spinocerebellar Ataxia Type 3, Fragile-X-Associated Tremor/Ataxia Syndrome, Frontotemporal Degeneration/Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia Type 31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents. Therefore, this invention may be included either in the whole pharmaceutical or medical field.

  本发明涉及苯并并芘衍生物作为药物的用途，主要用于预防和/或治疗肌无力型1型、亨廷顿病类2型、脊髓小脑共济失调型8型、肌无力型2型、脊髓小脑共济失调型3型、脆性X相关震颤/共济失调综合征、额颞叶退行性/肌萎缩侧索硬化和脊髓小脑共济失调型31型。在一个首选实施例中，本发明的苯并并芘衍生物也用作抗肌无力剂。因此，本发明可包括在整个制药或医学领域中。